Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
about
Visual dysfunction in Parkinson's diseaseExploring the Effects of Genetic Variants on Clinical Profiles of Parkinson's Disease Assessed by the Unified Parkinson's Disease Rating Scale and the Hoehn-Yahr StageNeuropsychiatric characteristics of GBA-associated Parkinson disease.Efficient Estimation of Nonparametric Genetic Risk Function with Censored Data.LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson's Disease.LRRK2 mutations in Parkinson's disease: confirmation of a gender effect in the Italian populationOlfactory identification in LRRK2 G2019S mutation carriers: a relevant marker?Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's diseaseInterest in genetic testing in Ashkenazi Jewish Parkinson's disease patients and their unaffected relativesGenetic markers of Restless Legs Syndrome in Parkinson diseaseSleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation CarriersAge-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium.Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers.The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus.Glucocerebrosidase activity in Parkinson's disease with and without GBA mutationsNovel recruitment strategy to enrich for LRRK2 mutation carriersNeurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson's Disease-Related LRRK2 G2019S Mutation.REM sleep behavior disorder, as assessed by questionnaire, in G2019S LRRK2 mutation PD and carriers.Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers.A Personalized Approach to Parkinson's Disease Patients Based on Founder Mutation AnalysisGenetic and Clinical Predictors of Deep Brain Stimulation in Young-Onset Parkinson's Disease.Estimation of genetic risk function with covariates in the presence of missing genotypes.A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers.Clinical Features of LRRK2 Carriers with Parkinson's Disease.Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease.Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.Arm swing as a potential new prodromal marker of Parkinson's disease.DYT16 revisited: exome sequencing identifies PRKRA mutations in a European dystonia family.Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation.Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.Inventory of real world data sources in Parkinson's disease.Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers.Progression in the LRRK2-Asssociated Parkinson Disease Population.Intact working memory in non-manifesting LRRK2 carriers--an fMRI study.The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.Tandem mass spectrometry assay of β-glucocerebrosidase activity in dried blood spots eliminates false positives detected in fluorescence assay.Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.Clinical Heterogeneity Among Variants in Parkinson's Disease: A Meta-AnalysisIsolated nigral degeneration without pathological protein aggregation in autopsied brains with LRRK2 p.R1441H homozygous and heterozygous mutations
P2860
Q26740467-0AC80FCA-8EBF-414B-8254-EB3922035771Q28396892-F4C58E39-311C-4123-8480-C9D5FD57FE71Q30275630-043E00A3-37DA-487B-BC9F-56A81604548EQ30998396-E5BFDF49-7FED-4FF4-8BAD-B7766D221823Q33561039-8B282B95-52E4-4C35-B123-3ABF980CC3B1Q34089529-354F30B8-9E41-4A5F-8202-274880716B86Q34562789-84DF14E1-E84F-4898-B94E-8A2EB19EBCEFQ35013928-07D0953F-F35F-402A-89B0-001EE6505292Q35091479-1A24EE20-94C2-4D36-8BCD-CB0F8E21D63DQ35638885-D6507DBD-0860-4A51-8652-6DD20924CBC9Q35692655-E11500FF-FA12-4850-9DD6-9A2CEA316D65Q35850713-B0F6337C-E49A-47D2-BD31-BF7670BE9BABQ35910498-6A6C1DB0-F0E2-47F2-BF2E-4CE02F30D89DQ35941370-31486D17-B4FB-43A1-974A-A276789AC893Q36041420-EE02046B-4EC2-4262-BFB4-5A4B5D4324F7Q36098631-B1C4FC8A-9B92-4356-8551-68F0780F2C6CQ36379938-DBFBB30A-E860-4444-B367-7D1485F8E060Q36470291-6C6D17CF-026F-4E9F-89DA-B8DB9E6A8475Q36706040-E422154D-6806-4782-AB8A-45474551799CQ36885946-DBA81955-EE35-48B0-A0CF-53CDFDA4506FQ37305731-9626AAA8-7EA1-4CD5-A67B-AC5519E07568Q38665765-CBEE5103-E50F-4EC0-B6AA-CC625F4546E9Q38843010-B0862203-C1F5-4939-AF0E-FEEB06F091D8Q39206423-596F204A-8E64-4E99-8D15-8D5530E7F966Q39686532-84A14100-1398-4BF7-A34C-5479A371E891Q39841718-98141CEA-E596-4860-919F-235FCCC6CE13Q39967268-B1A8559D-0072-4AAE-813E-89EF7ECB5F10Q41355527-2E9D7703-7D43-4BD0-ADC5-56050107998AQ42678271-065D0C6B-E805-44BE-B85F-091C5AECB6D2Q44561461-201D7C99-4557-463E-9FBB-F7FC9DC5BAF3Q46001147-0ED25DF2-838F-4EDC-9205-69976599DE4DQ47101523-07E3595C-2DB1-4D34-958A-13068E4B129EQ47139369-FFF611F8-0F1D-4D59-BC60-66729821233CQ47198236-2F98E61D-DDC9-4A7E-864A-DC885508322CQ47972063-85ABD7D6-0F87-49DE-AFF9-ECE7B4367BA0Q49886566-D95F694B-156E-451F-B585-0D7A82F737D4Q50178933-5E1B034B-E21A-434D-AC0B-1CFBC08DA956Q54117121-6517FE0B-A3C8-47E6-92A5-622816329497Q57072461-71326916-1EA8-436C-9434-D4FC242267F0Q58604362-C7C8CCD3-A5F7-4920-A6CE-75620DA6A4DE
P2860
Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
@en
Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
@nl
type
label
Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
@en
Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
@nl
prefLabel
Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
@en
Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
@nl
P2093
P2860
P50
P356
P1433
P1476
Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
@en
P2093
Anat Bar Shira
Anat Mirelman
Andres Deik
Ann L Hunt
Avner Thaler
Blair Ford
Brooke Johannes
Cheryl Waters
Christina Palmese
Deborah Raymond
P2860
P304
P356
10.1002/MDS.25647
P407
P50
P577
2013-10-15T00:00:00Z